NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering

EyePoint, Inc. (formerly EyePoint Pharmaceuticals, Inc.) recently secured a positive safety recommendation to continue its Phase 3 DURAVYU trials and filed a prospectus supplement for a Controlled Equity Offering of up to US$200,000,000 in common stock, while a major insider modestly reduced her holdings. The combination of a clean safety review for DURAVYU and a sizable at-the-market equity program highlights both the company’s clinical momentum and its need to fund a capital-intensive...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Expedia (EXPE): Assessing the Valuation After New Set Jetting Hub Launch and AI Leadership Appointment

Expedia Group (EXPE) just doubled down on two big themes driving its business by launching a Set Jetting travel hub for screen inspired trips and appointing its first chief AI and data officer. See our latest analysis for Expedia Group. Those moves come as momentum builds in the stock, with a 21.46% 3 month share price return and a 42.67% year to date share price return contributing to a 178.81% 3 year total shareholder return. If this kind of thematic growth story appeals to you, it could be...
NasdaqGM:APPN
NasdaqGM:APPNSoftware

Appian (APPN): Valuation Check After Healthcare AI Workflow Win at HL7 AI Challenge

Appian (APPN) just picked up global recognition in healthcare tech, with its joint “Bring AI to Work(flow)” solution winning the HL7 AI Challenge for interoperable and ethical AI driven workflows in patient care. See our latest analysis for Appian. That backdrop of validation seems to be feeding into sentiment, with a 90 day share price return of 31.54 percent pushing Appian to 29.68 percent year to date. However, the five year total shareholder return remains sharply negative and reminds...
NYSE:STT
NYSE:STTCapital Markets

State Street (STT): Reviewing Valuation After This Year’s 27% Share Price Gain

State Street (STT) has quietly ground out steady gains this year, and its recent move higher is catching more investor attention. With the stock up roughly 27% year to date, the question is whether that momentum still looks reasonable. See our latest analysis for State Street. The steady climb in State Street’s share price to about $124, alongside a 12.0% 3 month share price return and a 27.9% 1 year total shareholder return, suggests momentum is still building rather than fading. If you are...